Sanofi's Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma
Japan's Ministry of Health, Labour and Welfare has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous (SC) formulation for multiple myeloma. The approval covers both relapsed/refractory and newly diagnosed patients.
20 June 2026
Sanofi has received approval from Japan's Ministry of Health, Labour and Welfare for the subcutaneous (SC) formulation of Sarclisa (isatuximab). The drug is approved for use in combination with established treatment regimens for multiple myeloma (MM). This includes indications for relapsed or refractory MM (MM R/R) in combination with pomalidomide and dexamethasone (Pd), and for adult patients with newly diagnosed MM (MMND) in combination with bortezomib, lenalidomide, and dexamethasone (VRd).
Original source: sanofi.com